1. Home
  2. SGMT

SGMT

Sagimet Biosciences Inc. Series A

Logo Sagimet Biosciences Inc. Series A

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Founded: 2006 Country:
United States
United States
Employees: N/A City: SAN MATEO
Market Cap: 169.5M IPO Year: 2023
Target Price: $41.50 AVG Volume (30 days): 1.8M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.66 EPS Growth: N/A
52 Week Low/High: $2.13 - $20.71 Next Earning Date: 05-11-2024
Revenue: $2,000,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: